Drug news
Combination AZD 9291 + MEDI 4736 trials for NSCLC are halted- AstraZeneca
AstraZeneca has halted enrolment in two trials (Phase I TATTON and Phase III CAURAL studies) of combination AZD 9291 (mereletinib) + MEDI 4736 (durvalumab) due to an increase in interstitial lung disease which can lead to impaired pulmonary function and scarring. AstraZeneca sees the hold as temporary, and will provide patients enrolled in the trials with updated consent forms so they understand the new information and can make a decision on whether to continue participation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins